Tag: tocopherol

Vitamin E – the good and the bad

Klaus Sall

December 10. 2024

Vitamin E is a large family of active substances, with alpha-tocopherol being the most well-known and used, but it has good and bad relatives.

Atherosclerosis and cardiovascular disease are some of the most common causes of death worldwide, and also reduce the quality of life for millions of people. The authors of a new article have reviewed the recent scientific evidence on the effects of increased intake of the two main forms of vitamin E, tocotrienols and tocopherols, on patients with atherosclerosis and the cardiovascular diseases that accompany atherosclerosis (Rafique et al., 2024).

The article has focused on the fact that vitamin E is much more than the commonly known alpha-tocopherol, and that some of the other forms of vitamin E in the diet may contribute to better protection of the body’s cardiovascular system.

An attempt to illustrate the structure of vitamin E can be seen below, where the four tocotrienols are on the left with three double bonds in the long carbon chain, and the four tocopherols are on the right.

Tocotrienols                                                                  Tocopherols

Figure 1: The eight substances that naturally belong to the vitamin E group in plants. The tocotrienols are on the left, and the tocopherols on the right. Alpha-tocopherol is shown in red. The arrows in the figure show how trienols can be converted to alpha-tocopherol in our body. (Figure modified from Querchi et al. (2015)).

The new article is based on a review of 5 studies published in the 8 years from 2015-2022, which examined the effect of tocotrienol or tocopherol supplementation on the development of atherosclerosis or patients with already existing atherosclerosis and other cardiovascular diseases.

A study highlighted in the recently published article showed that tocotrienol at a dose of 250 mg per day for 16 weeks had a clear positive effect on reducing cholesterol and reducing important biomarkers of oxidative stress and inflammation in the body (Querishi et al 2015):

  • C-reactive protein (CRP): a 40% decrease

CRP is produced in the liver and is a frequently used marker for inflammation in the body in general and also for atherosclerosis, where a lower level gives patients a lower risk of having a blood clot.

  • Malondialdehyde (MDA): a decrease of 34%

Malondialdehyde is produced in the body’s tissues and high levels are a sign of oxidative stress and low antioxidant levels.

  • Gamma-glutamyl transferase (GGT): a decrease of 22%

High GGT levels in the blood are a sign of strain on the liver-biliary system and pancreas.

Along with the above positive changes, the total antioxidant status in the blood was increased by 22%, and cytokines that promote inflammation, such as interleukins (IL-1, IL-12), were reduced by 15-17%. Tocotrienol also had a positive effect on several types of micro-RNA, which are important in the regulation of inflammation and fatty acid metabolism.

Overall, the article showed that tocotrienol can help reduce the processes in the body that lead to atherosclerosis – especially in patients with already existing symptoms of cardiovascular problems.

However, the positive studies on tocotrienols mentioned in the new article are all of shorter duration – 3–6 months. In contrast, the studies the article compares with were all conducted with alpha-tocopherol, and of duration as long as 30 years.

These long-term studies of alpha-tocopherol have shown results with considerable variation. A Finnish study (Huang et al 2019), which followed 29,000 male smokers for 30 years, showed that a better diet with an approximately 30% higher content of natural alpha-tocopherol, initially reduced mortality by 22%, including atherosclerosis by 10-21%, heart attack by 2-17% and cerebral hemorrhage by 22-38%. A supplement of 50 mg/day RL alpha-tocopherol for approximately 6 years within the 30-year period, on the other hand, did not affect symptoms or mortality in the short or long term.

Another long-term American study followed 3,780 healthy women for 11 years, measuring the effect of an alpha-tocopherol supplement to double the level of alpha-tocopherol in the blood. The women were aged between 50 and 79 at the start of the study. The study found an 8% reduced incidence of cerebral hemorrhage with higher levels of alpha-tocopherol in the blood, but an increased incidence of other cardiovascular diseases, such that the overall incidence of cardiovascular problems increased by 8%.

Chemically produced “vitamin E”
Since vitamin E is a strong antioxidant that is known to reduce the unwanted oxidation of LDL cholesterol and other fats in the walls of cells, thereby counteracting atherosclerosis, etc. (Belcher et al 1993), it is relevant to ask why large and long-term studies do not unequivocally show that a supplement of vitamin E is super good.

One explanation could be that we somehow need free radicals, and that vitamin E, with its antioxidant effect, therefore removes something “good.” A more credible explanation, in my perspective, is that large-scale experiments have often used a cheap and poor form of chemically produced vitamin E.

When people talk about there being 8 forms of vitamin E, they are often referring to the 8 different molecules shown above (Figure 1). However, alpha-tocopherol is a complex molecule, and in three places in the molecule a carbon atom is linked to four other atoms/molecules. In the figure below, the positions of the three carbon atoms are marked with red stars (Figure 2).

Figure 2: Drawing of the molecular structure of alpha-tocopherol, where the stars mark the three places where a carbon has four different bonds. (Figure modified from Kohlmeier (2015)).

When you look at the drawing, you can easily imagine that the different molecules can rotate freely, but in reality they are very stable. If hydrogen (H) and the methyl molecule (CH3) are in just one of the places opposite to what is shown in the drawing – yes – then biologically you have seen a different molecule.

Unfortunately, this is exactly what happens when you produce vitamin E the old-fashioned chemical way. That is, atoms and molecules turn randomly, which means that they have two possible positions in three different places.

Therefore, 2 different x 2 different x 2 different = a total of 8 different forms of the molecule are chemically produced – see Figure 3 below. Of these, only one form is the natural form of vitamin E, which is found in plants and therefore in our diet, while the other seven versions of the molecule are unknown to plants and animals.

In particular, the four forms shown on the right in the figure below are broken down relatively quickly in the liver like other foreign substances. However, we know very little about what toxic effects they have before they are broken down, and what long-term toxic effects arise due to the more or less broken down substances.

Figure 3: Graphic illustration of the eight forms of vitamin E that are created when attempting to produce vitamin E using simple chemical methods. The natural alpha-tocopherol is marked in red. (Figure modified from Kohlmeier (2015)).

When you want to produce cheap supplements, such as cheap multivitamin pills, you often use chemically produced vitamin E. In these cheap products, the mixture of the eight forms of vitamin E is called rac alpha-tocopherol or DL ​​alpha-tocopherol. The natural alpha-tocopherol has been given first names such as D alpha-tocopherol or RRR alpha-tocopherol.

To increase the shelf life of various foods, vitamin E is often used as an antioxidant during production. Since the focus is on vitamin E’s antioxidant effect and not its effect as a vitamin, many manufacturers prefer to use the cheapest form of vitamin E, which is the chemically produced form that contains all 8 forms in equal amounts.

Figure 4 below graphically shows how the eight natural forms of vitamin E should be understood, compared to the seven additional forms that arise when alpha-tocopherol is produced chemically.

It can be seen that the variation in natural vitamin E is due to variation in the ring shown on the left, while the variation in chemically produced alpha-tocopherols is due to changes in the long chain extending from the rings.

Figure 4: At the top, the eight forms of vitamin E found in plants, and therefore naturally present in our diet, and then the eight forms of alpha-tocopherol – one natural and the other seven forms resulting from the chemical production of alpha-tocopherol, which are therefore also present in our diet when “vitamin E” is used as an antioxidant and in cheap dietary supplements. (The figure is modified from Kohlmeier (2015) and Querchi et al. (2015)).

Conclusion
It is now well documented that the different forms of vitamin E, in addition to their common effect as antioxidants, have quite different mechanisms of action in the body. The different natural forms of vitamin E contribute with different mechanisms to protect the body’s cardiovascular system, the central nervous system and also provide some protective effect against certain forms of cancer.

The chemical production of alpha-tocopherol, on the other hand, casts a shadow over the results achieved with long-term supplementation of alpha-tocopherol, so that it is not possible to determine whether a daily supplement of this vitamin E contributes to a healthy and long life or perhaps has negative effects.

Tocotrienols are always extracted from natural sources, and existing studies show that they have a safe effect even at relatively high daily intakes. It is therefore advantageous to choose a vitamin E with a high content of tocotrienols.

Klaus K. Sall
Biologist, Cand. Scient.
Sall&Sall Counseling

Notes

EFSA: The European Food Safety Authority EFSA estimates that a daily adequate intake of vitamin E measured as alpha tocopherol is 13 mg/day for men and 11 mg/day for women (EFSA 2015). In 2024, EFSA estimated that the highest daily intake for adults is 300 mg D alpha-tocopherol (EFSA 2024). In a previous specific case, EFSA estimated that a daily intake of 1000 mg mixed tocotrienols and tocopherols does not pose risks. (EFSA 2008).

Chirality: The eight forms of alpha-tocopherol that are formed during chemical production – are part of a phenomenon called chiral molecules. I have created a website that describes the importance of this phenomenon for all life (text in Danish): www.kiral.dk.

Mix: Studies have shown that alpha-tocopherol suppresses the body’s use of tocotrienols. Therefore, in supplements containing both alpha-tocopherol and tocotrienols, the tocopherols will be primarily utilized (Querishi et al 2015).

12: A total of 12 natural molecules have been found that have vitamin E effects. Four of them rarely occur in human food and are not known in dietary supplements.

Organic farming: In organic foods, it is not permitted to use the unnatural forms of alpha-tocopherol.

References and further reading

Belcher, J.D. et al. (1993) ‘Vitamin E, LDL, and endothelium. Brief oral vitamin supplementation prevents oxidized LDL-mediated vascular injury in vitro.’, Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 13(12), pp. 1779–1789. Available at: LINK.

EFSA (2008) ‘Opinion on mixed tocopherols, tocotrienol tocopherol and tocotrienols as sources for vitamin E added as a nutritional substance in food supplements, EFSA Journal, 6(3), p. 640. Available at: https://doi.org/10.2903/j.efsa.2008.640.

EFSA (2015) ‘Scientific Opinion on Dietary Reference Values for vitamin E as α-tocopherol’, EFSA Journal, 13(7), p. 4149. Available at: https://doi.org/10.2903/j.efsa.2015.4149.

EFSA (2024) ‘Scientific opinion on the tolerable upper intake level for vitamin E’, EFSA Journal, 22(8), p. e8953. Available at: https://doi.org/10.2903/j.efsa.2024.8953.

Huang, J. et al. (2019) ‘Relationship Between Serum Alpha-Tocopherol and Overall and Cause-Specific Mortality’, Circulation Research, 125(1), pp. 29–40. Available at: LINK.

Kohlmeier, M. (2015) Fat-Soluble Vitamins and Nonnutrients: Vitamin E, in: Nutrient Metabolism: Structures, Functions, and Genes, pp. 514–525. Elsevier. Available at: LINK.

Qureshi et al. (2015) ‘Pharmacokinetics and Bioavailability of Annatto δ-tocotrienol in Healthy Fed Subjects’, Journal of Clinical & Experimental Cardiology, 6(11). Available at: LINK.

Rafique, S. et al. (2024) ‘Comparative efficacy of tocotrienol and tocopherol (vitamin E) on atherosclerotic cardiovascular diseases in humans’, Journal of the Pakistan Medical Association, 74(6), pp. 1124–1129. Available at: https://doi.org/10.47391/JPMA.9227.

Sen, C. et al. (2000) ‘Molecular basis of Vitamin E action – Tocotrienol potently inhibits glutamate-induced pp60(c-Src) kinase activation and death of HT4 neuronal cells’, The Journal of biological chemistry, 275, pp. 13049–55. Available at: https://doi.org/10.1074/jbc.275.17.13049.

Sen, C.K. et al. (2007) ‘Tocotrienols: The Emerging Face of Natural Vitamin E’, Vitamins and hormones, 76, p. 203. Available at: https://doi.org/10.1016/S0083-6729(07)76008-9.

Vitamin E, Research references

Admin

January 1999

1. Ackerman Z et al. Neurological manifestations in celiac disease and vitamin E. J Clin Nutr 11; 5: 603-5, 1989.
2. Anderson TW et al. A double-blind trial of vitamin E in angina pectoris. Am J Clin Nutr 27:1174-8, 1974.
3. Adayeva Y et al. Vitamin E treatment in dystrophy of the macula lutea. Am J Ophthalmol 56:498, 1963.
4. Ayres S, Ihan R. Post-herpes Zoster neuralgia: Response to Vitamin E Therapy. Arch Dermatol 108:855-6, 1973.
5. Ayres S, Mihan R. Is vitamin E involved in the autoimmune mechanism? Cutis 21: 321-5, 1978.
6. Barboriak JJ et al. Vitamin E supplements and plasma high-density lipoprotein cholesterol. Am J Clin Pathol 77;3:371, 1982.
7. Bellizzi MC, Franklin MF, Duthie GG, et al. Vitamin E and coronary heart disease: The European paradox. Eur J Clin Nutr 48:822-31, 1994.
8. Bendich A, Machlin LJ. Safety of oral intake of vitamin E. Am J Clin Nutr 48: 612-619, 1988.
9. Bierenbaum M et al. Relationship between serum lipid peroxidation products in hypercholesterolemic subjects and vitamin E status. Biochem Int 28:57-66, 1992.
10. Blankenhorn G. Vitamin E: Clinical research from Europe. Nutr Dietary Consult June, 1988.
11. Bruce A et al. The effect of selenium and vitamin E on glutathione peroxidase levels and subjective symptoms in patients with arthrosis and rheumatoid arthritis, in Proc N Z Workshop on Trace Elements in N Z. Dunedin, U. of Otago, 92, 1981.
12. Block MT. Vitamin E in the treatment of diseases of the skin. Clin Med January pp. 31-4, 1953.
13. Burgess JF, Pritchard JE. Tocopherol (vitamin E) treatment of lupus erythematosus: Preliminary report. Arch Dermatol Syphilol 57: 953, 1948.
14. Burton GW, Ingold KU. Vitamin E as an in vitro and in vivo antioxidant. In: Diplock AT, Machoin LJ, Parker L, Pryor WA, eds. Vitamin E: Biochemistry and health implications. Ann NY Acad Sci 570: 7-22, 1989.
15. Carpenter KLH et al. Depletion of alpha-tocopherol in human atherosclerotic lesions. Free Rad Res 23:549- 58, 1995.
16. Cavarocchi NC et al. Superoxide generation during cardiopulmonary bypass: Is there a role for vitamin E? J Surg Res 40:519-27, 1986.
17. Chamiec T et al. Effects of antioxidant vitamins C and E on signal-averaged electrocardiogram and acute myocardial infarction. Am J Cardiol 77:237-41, 1996.
18. Chavance M. Nutrition, immunity, and illness in the elderly. New York: Pergamon Press. p 137-142, 1985.
19. Cheraskin E, Ringsdorf WM, Jr. Nutr Rep Int 2: 107-117, 1970.
20. Cloarec MJ et al. Alpha-tocopherol: Effect on plasma lipoproteins in hypercholesterolemic patients. Isr J Med Sci 23;8:869-72, 1987.
21. Cochrane T. Post-herpes Zoster neuralgia: Response to Vitamin E Therapy. Letter. Arch Dermatol 111:396, 1975.
22. Coghlan JG, Flitter WD, Clutton SM, et al. Lipid peroxidation and changes in vitamin E levels during coronary artery bypass grafting. J Thorac Cardiovasc Surg 106;2:268-74, 1993.
23. Comstock GW et al. Serum concentrations of alpha-tocopherol, beta-carotene, and retinol preceding the diagnosis of rheumatoid arthritis and systemic lupus erythematosus. Ann Rheum Dis 56: 323-5, 1997.
24. Creighton MO, Trevitchick JR. Cortical cataract formation prevented by vitamin E and glutathione. Exp Eye Res 29:6:689-93, 1979.
25. Creighton MO et al. Modelling cortical cataractogenesis: V. Steroid cataracts induced by Solu-medrol partially prevented by vitamin E in vitro. Exp Eye Res 37:1:65-76, 1983.
26. Creter D et al. Effect of vitamin E on platelet aggregation in diabetic retinopathy. Acta Hematol 62:74, 1979.
27. DeMaio SJ et al. Vitamin E supplementation, plasma lipids and incidence of restenosis after percutaneous transluminal coronary angioplasty PTCA. J Am Coll Nutr 11;1:68-73, 1992.
28. Dieber-Rotheneder M et al. Effect of oral supplementation with D-alpha-tocopherol on the vitamin E content of human low density lipoproteins and resistance to oxidation. J Lipid Res 32:1325- 32, 1991.
29. DiMascio P, Murphy M, Sies H. Antioxidant and defense systems. The role of carotenoids, tocopherols and thiols. Am J Clin Nutr 53: S194-200, 1991.
30. Dimitrov NV et al. Plasma tocopherol concentrations in response to supplements vitamin E. Am J Clin Nutr 1991; 53: 723-729, 1991.
31. Diplock AT, Machlin LJ, Packer L et al, eds. Daily vitamin E consumption and reported cardiovascular findings. New York: Ann NY Acad Sci. 1989: p 1-535, 1989.
32. Eldred GE. Vitamins A and E in RPE lipofuscin formation and implications for age-related macular degeneration. Prog Clin Biol Res 314:113-29, 1989.
33. Esterbauer H, Dieber-Rotheneder M, Striegl G et al. Role of vitamin E in preventing the oxidation of low-density lipoprotein. Am J Clin Nutr 1991; 53: 314S-321S.
34. Fahn S. A pilot trial of high-dose alpha-tocopherol and ascorbate in early Parkinson’s disease. Ann Neurol 32:S128-32, 1992; Fahn S. An open trial of high-dosage antioxidants in early Parkinson’s disease. Am J Clin Nutr 53:380S-1S, 1991.
35. Factor SA, Sanchez-Ramos JR, Weiner WJ. Vitamin E therapy in Parkinson’s disease. Adv Neurol 53:457-61, 1990.
36. Ferreira R et al. Antioxidant action of vitamins A and E in patients submitted to coronary bypass surgery. Vasc Surg 25:191-5, 1991.
37. Fink M, Fink J. Treatment of herpes simplex by alpha-tocopherol (Vitamin E). Br Dent J 148:246, 1980.
38. Fong JSC. Alpha-tocopherol. Its inhibition on human platelet aggregation. Experientia 32: 639-641, 1976.
39. Gaby WK et al. Vitamin intake and health: A scientific review. New York: Marcel Dekker. 1991: p 71-101.
40. Gey KF. Inverse correlation between plasma vitamin E and mortality from ischemic heart disease in cross-cultural epidemiology. Am J of Clin Nutr 53 (suppl.1); 326S-34S, 1991.
41. Giani E et al. Heated fat; vitamin E and vascular eicosanoids. Lipids 20: 439-448, 1985.
42. Haenszel W, Correa P, Lopez A et al. Serum micronutrient levels in relation to gastric pathology. Int J Cancer 36: 43-48, 1985.
43. Hayes KC. Retinal degeneration in monkeys induced by deficiencies of vitamin E or A. Invest Ophthalmol Vis Sci 13:7:499-510, 1974.
44. Hennig B et al. Protective effects of vitamin E in age-related endothelial cell injury. Int J Vitam Nutr Res 59:273-9, 1989.
45. Herbaczynska-Cedro K, Klosiewicz-Wasek B, Cedro K, et al. Supplementation with vitamins C and E suppresses leukocyte oxygen free radical production in patients with myocardial infarction. Eur Heart J 16: 1044-9, 1995.
46. Hermann WJ et al. The effect of tocopherol on high-density lipoprotein cholesterol: A clinical observation. Am J Clin Pathol 72:848-52, 1979.
47. Honkanen V et al. Vitamins A and E, retinol binding protein and zinc in rheumatoid arthritis. Clin Exp Rheumatol 7: 465-9, 1989.
48. Honkanen VEA et al. Serum cholesterol and vitamins A and E in juvenile chronic arthritis. Clin Exp Rheumatol 8: 187-91, 1990.
49. Horwitt MK. Supplementation with vitamin E. Am J Clin Nutr 47: 1088-1089, 1988.
50. Hu JJ et al. Effects of dietary supplementation of alpha-tocopherol on plasma glutathione and DNA repair activities. Canc Epidemiol Biomark Preven 5; (4): 263-70, 1996.
51. Jacques PF. Chylack antioxidant status in persons with and without senile cataract. Arch Ophthalmol 106: 337-340, 1988.
52. Jain SK, McVie R, Jaramillo JJ, et al. The effect of modest vitamin E supplementation on lipid peroxidation products and other cardiovascular risk factors in diabetic patients. Lipids 31:S87-90, 1996.
53. James S et al. Effekter av selenvitamin E-behandling till kvinnor med lång variga arbetsrelaterade nack-och skuldersmärtor. En dubbelblindstudie. Läkaresällskapets Riksstämma, 1985.
54. Jandak J et al. Reduction of platelet adhesiveness by vitamin E supplementation in humans. Thrombosis Res 49:393-404, 1988.
55. Jandak J et al. Alpha tocopherol, an effective inhibitor of platelet adhesion. Blood 73:141-9, 1989.
56. Jialal I, Grundy SM. Effect of dietary supplementation with alpha-tocopherol on the oxidative modification of low density lipoprotein. J Lipid Res 33;6:899-906, 1992.
57. Jialal L, Fuller CJ, Hunt BA. The effect of alpha-tocopherol supplementation on LDL oxidation. Arterioscler Thromb Vasc Biol 15:190-8, 1995.
58. Juhlin L et al. Blood glutathione-peroxidase levels in skin diseases: Effect of selenium and vitamin E treatment. Acta Derm Venereal (Stockh) 62; 3: 211-4, 1982.
59. Knekt P et al. Serum vitamin E level and risk of cancer among Finnish men during a 10-year follow-up. Am J Epidemiol 127: 28-41, 1988.
60. Kneckt P. Serum vitamin E level and risk of female cancers. Int J Epidem 17: 281-286, 1988.
61. Knekt P, Aromaa A, Maatela J et al. Vitamin E and cancer prevention. Am J Clin Nutr 53: 283S-286S, 1991.
62. Kok FJ, de Bruijn AM, Vermeeren R et al. Serum selenium, vitamin antioxidants, and cardiovascular mortality. N Eng J Med 316: 1416, 1987.
63. London R.S. et al. Endocrine Parameters and Alpha-Tocopherol Therapy of Patients with Mammary Dysplasia, Cancer Res 41; 3811-3, 1981.
64. London RS, et al. The Effect of Alpha-tochopherol on Premenstrual Symptomatology: A Double-blind Study. II Endocrine Correlates, J Am Col Nutr 3 : 351-6, 1984.
65. Losonczy, KG, Harris, TB, Havlik, RJ. Vitamin E and vitamin C supplement use and risk of all-cause and coronary heart disease mortality in older persons. The established populations for epidemiologic studies of the elderly. Am J Clin Nutr 64: 190-196, 1996.
66. Machlin LJ. Use and safe of elevated dosages of vitamin E in adults. Int J Vitam Nutr Res Suppl 30: 56-68, 1989.
67. Machtey I, Ouaknine, L. Tocopherol in osteoarthritis: A controlled pilot study. J Am Geriatr Soc 26: 328-30, 1978.
68. Mauro A, Orsi L, Mortara P, et al. Cerebellar syndrome in adult celiac disease with vitamin E deficiency. Acta Neurol Scand 84; 2:167-70, 1990.
69. Menkes MS, Comstock GW, Vuilleumier JP et al. Serum beta carotene vitamins A and E, selenium, and the risk of lung cancer. N Eng J Med 315: 1250-1254, 1986.
70. Meydani M et al. Muscle uptake of vitamin E and its association with muscle fiber type. Nutr Biochem 8: 74-78, 1997.
71. Mezes M, Bartosiewicz G. Investigations on vitamin E and lipid peroxide status in rheumatic diseases. Clin Rheumatol 2; 3: 259-63, 1983.
72. Mezzetti A, Lapenna D, Pierdomenico SD, et al. Vitamins E, C and lipid peroxidation in plasma and arterial tissue of smokers and nonsmokers. Atherosclerosis 112: 91-9, 1995.
73. Miwa K, Miyagi Y, Igawa A, et al. Vitamin E deficiency in variant angina. Circulation 94;1:14-18, 1996.
74. Miyamoto H, Araya Y, Ito M et al. Serum selenium and vitamin E. concentrations in families of lung cancer patients. Cancer 60: 1159-1162, 1987.
75. Muckle T, Hazir D. Variation in human blood high-density lipoprotein response to oral vitamin E megadosage. Am J Clin Pathol 91: 165-71, 1989.
76. Munthe E, Aaseth J. Treatment of Rheumatoid Arthritis with Selenium and Vitamin E. Scan J of Rheumatol 53; (suppl.): 103, 1984.
77. Nead DE. Effective vitamin E treatment for ulcerative herpetic lesions. Dent Survey 52; (7):50-1, 1976.
78. Niki E, Yamamoto Y, Komuro E et al. Membrane damage due to lipid oxidation. Am J Clin Nutr  53: S201-205, 1991.
79. Novelli GP et al. Vitamin E protects human skeletal muscle from damage during surgical ischemia-reperfusion. Am J Surg March 173: 206-9, 1997.
80. Odeleye OE, Watson RR. The potential role of vitamin E in the Treatment of immunologic abnormalities during Acquired Immune Deficiency Syndrome. Prog Food Nutr Sci 15; (1-2):1-19, 1991.
81. Pacht ER, Kaseki H, Mohammed JR et al. Deficiency of vitamin E in the alveolar fluid of cigarette smokers. J Clin Invest 77: 789-798, 1986.
82. Paolisso G et al. Cronic Intake of Pharmacological Doses of Vitamin E Might be Useful in the Therapy of Elderly Patients with Coronary Heart Disease. Am J Clin Nutr 61: 848-52, 1995.
83. Pascoe GA, Fariss MW, Olafsdottir K et al. A role of vitamin E in protection against cell injury. Maintenance of intracellular glutathione precursors and biosynthesis. Eur J Biochem 166: 241-247, 1987.
84. Prasad JS. Effect of vitamin E supplementation on leukocyte function. Am J Clin Nutr 33: 606-608, 1980.
85. Princen H, van Poppel G, Vogelezang C, et al. Supplementation with vitamin E but not beta carotene in vivo protects low density lipoprotein from lipid peroxidation in vitro: Effect of cigarette smoking. Arter Throm 12: 554-62, 1992.
86. Princen HM et al. Supplementation with low doses of vitamin E protects LDL from lipid peroxidation in men and women. Arterioscler Thromb Vasc Biol 15: 325-33, 1995.
87. Pryor WA. Can vitamin E protect humans against the pathological effects of ozone in smog? Am J Clin Nutr 53: 702-722, 1991.
88. RabinovitchR et al. Neuromuscular disorders amenable to wheat germ oil therapy. J Neurol Neurosurg Psychiatry 14: 95-100, 1951.
89. Reddy ACP, Lokesh BR. Dietary unsaturated fatty acids, vitamin E, curcumin and eugenol
90. alter serum and liver lipid peroxidation in rats. Nutr Res 14: 1423-37, 1994.
91. Regnström J, Nilsson J, Moldeus P, et al. Inverse relation between the concentration of low-density- lipoprotein vitamin E and severity of coronary artery disease. Am J Clin Nutr 63: 377-85, 1996.
92. Riemersma RA, Wood DA, MacIntyre CCH, et al. Risk of angina pectoris and plasma concentrations of vitamins A, C and E and carotene. Lancet 337: 1-5, 1991.
93. Riemersma RA, Wood DA, MacIntyre CCA et al. Low plasma vitamins E and C increased risk of angina in Scottish men. In: Diplock AT, Machlin LJ, Packer L et al, eds. Vitamin E: Biochemistry and health implications, vol. 570. New York: Ann NY Acad Sci. p 291-295, 1989.
94. Robertson JM, Donner AP, Trevithick JR. Vitamin E: Biochemistry and health implications, vol. 570. New York: Ann NY Acad Sci. p 372-382, 1989.
95. Robertson JM, Donner AP, Trevithick JR. Vitamin E intake and risk of cataracts in humans. Ann NY Acad Sci 570: 372-378, 1989.
96. Robertson JM et al. Vitamin E intake and risk of cataracts in humans. Ann N Y Acad Sci 570: 372-82, 1989.
97. Robison WG Jr et al. Vitamin E deficiency and the retina: Photoreceptor and pigment epithelial changes. Invest Ophthalmol Vis Sci 18:7:683-90, 1979.
98. Romeo G. The therapeutic effect of vitamins A and E in neurosensory hearing loss. Acta Vitaminol Enzymol 7 Suppl:85-92, 1985.
99. Ross WM et al. Modelling cortical cataractogenesis: III. In vivo effects of vitamin E on cataractogenesis in diabetic rats. Can J Ophthalmol 17:2: 61-6, 1982.
100. Ross WM et al. Radiation cataract formation diminished by vitamin E in rat lenses in vitro. Exp Eye Res 36:5: 645-53, 1983.
101. Ross WM, Creighton MO, Trevithick JR. Radiation cataractogenesis induced by neutron or gamma irradiation in the rat lens is reduced by vitamin E. Scan Micros 4: 641-50, 1990.
102. Rouhiainen P, Rouhiainen H, Salonen J, et al. Association between low plasma vitamin E concentration and progression of early cortical lens opacities. Am J Epidemiol 144: 5: 496-500, 1996.
103. Sahyoun NR et al. Carotenoids, vitamins C and E, and mortality in an elderly population. Am J Epidemiol 144:5:501-11, 1996.
104. Saito T. The preventive effect of vitamin E on gallstone formation. (1). A study of biliary cholesterol and bile acids in vitamin E-deficient hamsters. Arch Jpn Chir 56; 3: 247-61, 1987.
105. Salonen JT, Salonen R, Lappetelainen R et al. Risk of cancer in relation to serum concentrations of selenium and vitamins A and E. matched case-control analysis of prospective data. Br Med J 290: 417-420, 1985.
106. Salonen JT et al. Increased Risk of Non-Insulin Diabetes Mellitus at Low Plasma Vitamin E Concentrations: A Four-Year Follw-up Study in Men. Br Med J 311: 1124-27, 1995.
107. Schwartz ER. The modulation of osteoarthritic development by vitamins C and E. Int J Vitam Nutr Res Suppl. 26: 141-6, 1984.
108. Seddon JM, Ajani UA, Sperduto RD, et al. Dietary carotenoids, vitamins A, C, and E, and advanced age-related macular degeneration. JAMA 272:1413-20, 1994.
109. Simon E et al. Plasma and erythrocyte vitamin E content in asymptomatic hypercholesterolemic subjects. Clin Chem 43:2:285-9, 1997.
110. Simons LA, Von Konigsmark M, Balasubramaniam S. What dose of vitamin E is required to reduce susceptibility of LDL to oxidation? Aust N Z J Med 26;4:496-503, 1996.
111. Sklodowska M, Wasowicz W, Gromnadzinska J, et al. Selenium and vitamin E concentrations in plasma and erythrocytes of angina pectoris patients. Trace Elem Med 8:113-17, 1991.
112. Sklodowska M et al. Vitamin E, thiobarbituric acid reactive substance concentrations and superoxide dismutase activity in the blood of children with juvenile rheumatoid arthritis. Clin Exp Rheumatol 14: 433-9, 1996.
113. Sokol RJ. Vitamin E. In: Ziegler EE, Filer LJ Jr, eds. Present knowledge in nutrition. 7th edn. Washington DC: International Life Sciences Press. p 130-136, 1996.
114. Stampfer M, Hennekens C, Manson J, et al. Vitamin E consumption and the risk of coronary heart disease in women. N Engl J Med 328:1444-9, 1993.
115. Starasoler S, Haber GS. Use of vitamin E oil in primary herpes gingivostomatitis in an adult. N Y State Dent J 44; (9):382-3, 1978.
116. Steinberg CL. Vitamin E and collagen in the rheumatic diseases. Ann N Y Acad Sci 52:380-9, 1949.
117. Steiner M. Effect of alpha-tocopherol administration on platelet function in man. Thromb Haemostas 49: 73-77, 1983.
118. Steiner M. Influence of vitamin E on platelet function in humans. J Am Coll Nutr 10;5:466-73, 1991.
119. Steiner M, Glantz M, Lekos A. Vitamin E plus aspirin compared with aspirin alone in patients with transient ischemic attacks. Am J Clin Nutr 62; suppl:1381S-4S, 1995.
120. Stephens NG, Parsons A, Schofield PM, et al. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study CHAOS. Lancet 347:781-6, 1996.
121. Stone WL et al. Effects of dietary selenium and vitamin E on plasma lipoprotein cholesterol levels in male rats. Ann Nutr Metab 30: 94-103, 1986.
122. Street DA et al. Serum antioxidants and myocardial infarction: Are low levels of carotenoids and alpha-tocopherol risk factors for myocardial infarction? Circulation 90; 3:1154-61, 1994.
123. Suzukawa M, Ishikawa T, Yoshida H, Tokorozawa N. Effect of in-vivo supplementation with low-dose vitamin E on susceptibility of low-density lipoprotein and high-density lipoprotein to oxidative modification. J Am Coll Nutr 14:1:46-52, 1995.
124. Suzuki T, Kawase T, Harada T. Clinical study of vitamin E status in patients with chronic liver diseases. Nippon Shokakibyo Gakkai Zasshi 88; 4:1066-73, 1991.
125. Sword J, Pope A, Hoekstra W. Endotoxin and lipid peroxidation in vitro in selenium and vitamin E deficient and adequate rat tissue. J Nutr 121: 251-257, 1991.
126. Sword J, Pope A, Hoekstra W. Endotoxin and lipid peroxidation in vitro in selenium and vitamin E deficient and adequate rat tissue. J Nutr 121: 258-264, 1991.
127. Takamatsu S, Takamatsu M, Satoh K, et al. Effects on health of dietary supplementation with 100 mg d-alpha tocopheryl acetate, daily for 6 years. J Int Med Res 23:342-57, 1995.
128. Tang AM et al. Association between Serum Vitamin A and E levels and HIV-1 disease progression. AIDS 11:613-20, 1997.
129. Taylor A. Associations between nutrition and cataract. Nutr Rev 47: 225-234, 1989.
130. Tolonen M, Markku H, Sarna S. Vitamin E and selenium supplementation in geriatric patients A double-blind preliminary clinical trial. Biol Trace Elem Res 7: 161-168, 1985.
131. Torun M et al. Serum levels of vitamin E in relation to cardiovascular diseases. J Clin Pharm Therap 20:335-40, 1995.
132. Van Den Berg JJ, Roelofsen B, OpdenKamp JAF et al. Vitamin E: Biochemistry and health implications, vol. 570. New York: Ann NY Acad Sci. p 527-529, 1989.
133. Veris Research Summary. The role of antioxidants in prevention of coronary heart disease. p 1-16, Nov. 1996.
134. Verlangieri AJ, Bush MJ. Effects of d-a-tocopherol supplementation on experimentally induced primate atherosclerosis. J Am Coll Nutr 11;2:131-8, 1992.
135. Vitale S et al. Plasma vitamin C, E and beta carotene levels and risk of cataract. Invest Ophthalmol Vis Sci 32:723, 1991.
136. Wald NJ, Boreham J, Hayward JL et al. Plasma retinol beta carotene and vitamin E levels in relation to future risk of breast cancer. Br J Cancer 49: 321-324, 1984.
137. Wang Y, Watson RR. Potential Therapeutics of Vitamin E (Tocopherol) in AIDS and HIV, Drugs 48:327-38, 1994.
138. Weisburger J. Nutritional approach to cancer prevention with emphasis on vitamins, antioxidants and carotenoids. Am J Clin Nutr 53: S226-237, 1991.
139. Welsh AL. Lupus erythematosus: Treatment by combined use of massive amounts of pantothenic acid and vitamin E. Arch Dermatol Syphilol 70: 181-98, 1954.
140. White G. Vitamin E inhibition of platelet prostaglandin biosynthesis. Fed Proc 36: 350, 1977.
141. Yau TM, Weisel RD, Mickle DA, et al. Vitamin E for coronary bypass operations. A prospective, double-blind, randomized trial. J Thorac Cardiovasc Surg 108; 2: 302-10, 1994.
142. Örndahl G et al. Myotonic dystrophy treated with selenium and vitamin E. Acta Med Scand 219: 409-44, 1986.

 

Sources
Joseph E. Pizzorno Jr., Michael T. Murrey & Melvyn R. Werbach.